Business Description
Definium Therapeutics Inc
NAICS : 325190
SIC : 2834
ISIN : CA60255C8850
Share Class Description:
FRA:MMQ0: Ordinary SharesTotal Employee Number:
106Description
Definium Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. Its lead candidate, DT120 ODT, is an orally disintegrating tablet being evaluated in late-stage Phase 3 trials for generalized anxiety disorder (GAD) and major depressive disorder (MDD), and has received FDA Breakthrough Therapy Designation for GAD. The company's approach aims to address underlying causes of these conditions and offer durable remission rather than temporary symptom relief. Definium operates as a single reportable segment centered on research and development of its neurological drug development platform. It is also building commercial and operational capabilities in anticipation of a potential launch of DT120 ODT, if approved. The company is based in the United States and, as a clinical-stage enterprise, does not yet generate product revenue, relying on financing to fund its research, development, and pre-commercial activities.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 29.72 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.11 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 0.8 | |||||
3-Year EPS without NRI Growth Rate | 5 | |||||
3-Year FCF Growth Rate | 3.2 | |||||
3-Year Book Growth Rate | -5.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 36.91 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 50 | |||||
9-Day RSI | 48.49 | |||||
14-Day RSI | 47.77 | |||||
3-1 Month Momentum % | 78.4 | |||||
6-1 Month Momentum % | 135.29 | |||||
12-1 Month Momentum % | 363.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.95 | |||||
Quick Ratio | 6.95 | |||||
Cash Ratio | 6.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -37.5 | |||||
Shareholder Yield % | -20.58 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -95.83 | |||||
ROA % | -72.02 | |||||
ROIC % | -242.36 | |||||
3-Year ROIIC % | -293.09 | |||||
ROCE % | -85.15 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 6.04 | |||||
Price-to-Tangible-Book | 6.16 | |||||
EV-to-EBIT | -12.09 | |||||
EV-to-EBITDA | -12.09 | |||||
EV-to-Forward-EBITDA | -15.11 | |||||
EV-to-Forward-Revenue | 343.82 | |||||
EV-to-FCF | -24.89 | |||||
| Price-to-Net-Current-Asset-Value | 6.17 | |||||
| Price-to-Net-Cash | 6.23 | |||||
Earnings Yield (Greenblatt) % | -8.28 | |||||
FCF Yield % | -3.18 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Definium Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.95 | ||
| Beta | 3.0574 | ||
| 3-Year Sharpe Ratio | 1.13 | ||
| 3-Year Sortino Ratio | 3.14 | ||
| Volatility % | 112.83 | ||
| 14-Day RSI | 47.77 | ||
| 14-Day ATR (€) | 2.021152 | ||
| 20-Day SMA (€) | 33.995 | ||
| 12-1 Month Momentum % | 363.7 | ||
| 52-Week Range (€) | 7.535 - 42.7 | ||
| Shares Outstanding (Mil) | 134.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Definium Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Definium Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 16:30 | In 158 days | ||
| Annual report for 2026 | 2027-02-26 | In 157 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 157 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 16:30 | In 46 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 45 days | ||
| TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit | 2026-09-23 09:30 | In 2 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 16:30 | 37.50 (+5.93%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 37.50 (+5.93%) | ||
| General meeting for 2026 | 2026-06-11 10:00 | 20.70 (+3.50%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 15:10 | 19.55 (-2.74%) |
Show
Entries
Definium Therapeutics Inc Frequently Asked Questions
What is Definium Therapeutics Inc(FRA:MMQ0)'s stock price today?
The current price of FRA:MMQ0 is €33.40. The 52 week high of FRA:MMQ0 is €42.70 and 52 week low is €7.54.
When is next earnings date of Definium Therapeutics Inc(FRA:MMQ0)?
The next earnings date of Definium Therapeutics Inc(FRA:MMQ0) is 2026-11-06 Est..
Does Definium Therapeutics Inc(FRA:MMQ0) pay dividends? If so, how much?
Definium Therapeutics Inc(FRA:MMQ0) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers